Business
Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V...
About this update from Rakovina Therapeutics Inc
[{"type":"text","content":"Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update\n\n\n\n VANCOUVER, British Columbia, April 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery announced the financial results for its fourth quarter and fiscal year ending December 31, 2024 and provided a corporate update.\n \n\n\n 2024 Highlights and Recent Developments\n \n\n\n\n On April 29, 2025, we announced the intention to appoint Yevgeniy Meshcherekov and David Kideckel to the Company’s board of directors, subject to receiving approval from the TSX Venture Exchange. The Company also announces that Michael Liggett has retired from the Board. Subject to TSXV approval, Mr. Meshcherekov will replace Mr. Liggett as the chair of the audit committee of the Board\n \n\n On April 28 & 29, 2025, we presented pre-clinical data related to the development of our kt-2000 and kt-5000 programs at the American Association of Cancer Research (AACR) annual meeting. These data demonstrate that select candidates derived from our AI collaborations may meet our target product profile for a PARP-1 selective lead candidate (kt-2000) and for an ATR-inhibitor (kt-5000).\n \n\n On March 12, 2025, we announced that we had received the first synthesized batch of AI-generated ATR inhibitor compounds developed in collaboration with Variational AI.\n \n\n On January 30, 2025, we announced the listing of common shares on the Frankfurt Stock Exchange (FSE) under the ticker symbol “7J0”.\n \n\n On January 13, 2025, we announced the successful achievement of a shortlist of AI-generated molecules targeting ATR (Ataxia Telangiectasia and Rad3-related protein) with specific designs for central nervous system (CNS) penetration.\n \n\n On January 6, 2025, we announced the receipt of initial synthesized drug candidates: AI-generated PARP-inhibitor compounds for\n \n in vitro\n \n and\n \n in vivo\n \n validation in our laboratories.\n \n\n On December 13, 2024, we announced the closing of an oversubscribed $3.0 million private placement offering (the “Private Placement”). The Private Placement consists of 50,000,000 units (the “Units”) at a price of $0.06 per Unit....